<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-04-21" updated="2020-01-02">
  <drugbank-id primary="true">DB09040</drugbank-id>
  <name>Efinaconazole</name>
  <description>Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.</description>
  <cas-number>164650-44-6</cas-number>
  <unii>J82SB7FXWB</unii>
  <average-mass>348.398</average-mass>
  <monoisotopic-mass>348.17616767</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7635</ref-id>
        <pubmed-id>24249649</pubmed-id>
        <citation>Patel T, Dhillon S: Efinaconazole: first global approval. Drugs. 2013 Nov;73(17):1977-83. doi: 10.1007/s40265-013-0152-x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated in the treatment of fungal infection of the nail, known as onychomycosis.</indication>
  <pharmacodynamics>mean ± SD plasma Cmax on Day 28 of treatment: 0.67 ± 0.37 ng/mL.&#13;
mean ± SD AUC was 12.15 ± 6.91 ng*h/mL.</pharmacodynamics>
  <mechanism-of-action>Efinaconazole is an azole antifungal. Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>29.9 hours in healthy patients. </half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</description>
    <direct-parent>Amphetamines and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Phenethylamines</subclass>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Fluorobenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylpropanes</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <alternative-parent>Triazoles</alternative-parent>
    <substituent>1,2,4-triazole</substituent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Amine</substituent>
    <substituent>Amphetamine or derivatives</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Fluorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylpropane</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Tertiary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="iupac">(2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol</synonym>
    <synonym language="spanish" coder="inn">efinaconazol</synonym>
    <synonym language="english" coder="inn/usan">Efinaconazole</synonym>
  </synonyms>
  <products>
    <product>
      <name>Jublia</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413388</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jublia</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-5400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA203567</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Jublia</name>
      <ingredients>Efinaconazole</ingredients>
    </mixture>
    <mixture>
      <name>Jublia</name>
      <ingredients>Efinaconazole</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antifungal Agents</category>
      <mesh-id>D000935</mesh-id>
    </category>
    <category>
      <category>Antifungals for Dermatological Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antifungals for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Azole Antifungals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Imidazole and Triazole Derivatives</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Candida albicans and other yeasts</affected-organism>
    <affected-organism>Yeast and other Trichophyton or Microsporum fungi</affected-organism>
    <affected-organism>Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>100 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D01AC19">
      <level code="D01AC">Imidazole and triazole derivatives</level>
      <level code="D01A">ANTIFUNGALS FOR TOPICAL USE</level>
      <level code="D01">ANTIFUNGALS FOR DERMATOLOGICAL USE</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>84:04.08.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09040.pdf?1429637231</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09040.pdf?1429724819</msds>
  <patents>
    <patent>
      <number>7214506</number>
      <country>United States</country>
      <approved>2007-05-08</approved>
      <expires>2021-10-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8039494</number>
      <country>United States</country>
      <approved>2011-10-18</approved>
      <expires>2030-07-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8486978</number>
      <country>United States</country>
      <approved>2013-07-16</approved>
      <expires>2030-10-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9302009</number>
      <country>United States</country>
      <approved>2016-04-05</approved>
      <expires>2030-10-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9662394</number>
      <country>United States</country>
      <approved>2017-05-30</approved>
      <expires>2034-10-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9566272</number>
      <country>United States</country>
      <approved>2017-02-14</approved>
      <expires>2028-01-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9861698</number>
      <country>United States</country>
      <approved>2018-01-09</approved>
      <expires>2030-07-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9877955</number>
      <country>United States</country>
      <approved>2018-01-30</approved>
      <expires>2028-01-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10105444</number>
      <country>United States</country>
      <approved>2018-10-23</approved>
      <expires>2030-07-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.49</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.10e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>348.398</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>348.17616767</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H22F2N4O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NFEZZTICAUWDHU-RDTXWAMCSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>54.18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>103.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>34.48</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>7.45</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22151</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>82718</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>489181</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310264988</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10021</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>428538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Efinaconazole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2103877</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/efinaconazole-topical.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000690</id>
      <name>Lanosterol 14-alpha demethylase</name>
      <organism/>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7635</ref-id>
            <pubmed-id>24249649</pubmed-id>
            <citation>Patel T, Dhillon S: Efinaconazole: first global approval. Drugs. 2013 Nov;73(17):1977-83. doi: 10.1007/s40265-013-0152-x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P50859" source="Swiss-Prot">
        <name>Lanosterol 14-alpha demethylase</name>
        <general-function>Sterol 14-demethylase activity</general-function>
        <specific-function>Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol (By similarity).</specific-function>
        <gene-name>ERG11</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.07</theoretical-pi>
        <molecular-weight>61304.95</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="237561">Yeast</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L40389</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>755693</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P50859</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP51_CANGA</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.13.70</synonym>
          <synonym>CYP51</synonym>
          <synonym>CYPLI</synonym>
          <synonym>Cytochrome P450 51</synonym>
          <synonym>Cytochrome P450-14DM</synonym>
          <synonym>Cytochrome P450-LIA1</synonym>
          <synonym>Sterol 14-alpha demethylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010481|Lanosterol 14-alpha demethylase
MSTENTSLVVELLEYVKLGLSYFQALPLAQRVSIMVALPFVYTITWQLLYSLRKDRPPLV
FYWIPWVGSAIPYGTKPYEFFEDCQKKYGDIFSFMLLGRIMTVYLGPKGHEFIFNAKLAD
VSAEAAYSHLTTPVFGKGVIYDCPNHRLMEQKKFVKGALTKEAFVRYVPLIAEEIYKYFR
NSKNFKINENNSGIVDVMVSQPEMTIFTASRSLLGKEMRDKLDTDFAYLYSDLDKGFTPI
NFVFPNLPLEHYRKRDHAQQAISGTYMSLIKERREKNDIQNRDLIDELMKNSTYKDGTKM
TDQEIANLLIGVLMGGQHTSAATSAWCLLHLAERPDVQEELYQEQMRVLNNDTKELTYDD
LQNMPLLNQMIKETLRLHHPLHSLFRKVMRDVAIPNTSYVVPRDYHVLVSPGYTHLQEEF
FPKPNEFNIHRWDGDAASSSAAGGDEVDYGFGAISKGVSSPYLPFGGGRHRCIGELFAYC
QLGVLMSIFIRTMKWRYPTEGETVPPSDFTSMVTLPTAPAKIYWEKRHPEQKY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010482|Lanosterol 14-alpha demethylase (ERG11)
ATGTCCACTGAAAACACTTCTTTGGTCGTTGAACTATTGGAGTACGTGAAGCTTGGTCTT
TCGTACTTCCAAGCTCTGCCATTGGCGCAGAGAGTGTCTATTATGGTCGCCTTGCCATTT
GTGTACACCATCACATGGCAATTGCTTTACTCCTTGAGAAAGGACAGACCACCACTTGTG
TTCTACTGGATCCCATGGGTCGGCTCTGCTATCCCATACGGTACCAAGCCATACGAGTTC
TTCGAAGACTGCCAAAAGAAATACGGTGATATCTTCTCTTTCATGCTATTGGGTAGAATT
ATGACTGTCTACTTGGGTCCAAAGGGTCACGAATTCATCTTCAACGCCAAGTTGGCCGAT
GTTTCCGCTGAAGCTGCTTACTCCCACTTGACCACCCCAGTGTTCGGTAAAGGTGTTATC
TACGATTGTCCAAACCACAGACTAATGGAACAAAAGAAGTTTGTCAAGGGTGCTTTGACT
AAGGAAGCCTTTGTCAGATACGTTCCATTGATCGCTGAGGAAATCTACAAGTACTTCAGA
AACTCCAAGAACTTCAAGATCAACGAAAACAACTCCGGTATCGTCGACGTTATGGTCTCC
CAACCTGAAATGACTATCTTCACTGCTTCCAGATCCTTGCTAGGTAAGGAAATGAGAGAC
AAGTTGGACACCGACTTCGCTTACTTGTACAGTGACTTGGACAAGGGTTTCACCCCAATT
AACTTCGTCTTCCCTAACTTGCCTCTAGAACACTACAGAAAGAGAGATCATGCCCAACAA
GCTATCTCTGGTACTTACATGTCCTTGATTAAGGAAAGACGTGAGAAGAACGATATCCAA
AACCGTGACTTGATTGATGAATTGATGAAGAACTCCACTTACAAGGATGGTACTAAGATG
ACCGACCAAGAAATTGCCAACCTATTGATTGGTGTCTTGATGGGTGGTCAACATACTTCC
GCTGCTACCTCCGCTTGGTGTCTATTGCATTTGGCTGAAAGACCAGATGTCCAAGAAGAA
TTATACCAAGAACAAATGCGCGTCTTGAACAACGATACCAAGGAATTGACTTACGATGAC
CTACAAAACATGCCTCTATTGAACCAAATGATCAAGGAAACTTTGAGATTGCACCACCCA
TTGCACTCTTTGTTCCGTAAAGTCATGAGAGATGTCGCTATTCCAAACACTTCCTACGTT
GTCCCAAGGGACTACCACGTTCTAGTCTCCCCAGGTTACACTCACTTGCAAGAAGAATTC
TTCCCTAAGCCAAATGAATTCAACATCCACCGTTGGGACGGTGATGCTGCTTCTTCCAGT
GCTGCTGGTGGTGACGAAGTTGATTACGGTTTCGGTGCTATCTCCAAGGGTGTTTCCTCT
CCATACTTGCCATTCGGTGGTGGTAGACACAGATGTATCGGTGAATTGTTCGCTTACTGT
CAATTGGGTGTGTTGATGTCCATTTTCATCAGAACCATGAAATGGCGTTACCCAACTGAA
GGTGAAACTGTCCCACCATCTGACTTCACCTCCATGGTCACCCTACCAACTGCCCCTGCT
AAGATCTACTGGGAAAAGAGACATCCAGAACAAAAGTACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol 14-demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ergosterol biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>